Genmab drops ProfoundBio-derived ADC as it refocuses oncology portfolio

17 September 2025

Genmab (CSE: GMAB) has ended development of GEN1107, an antibody-drug conjugate (ADC) it gained through its $1.8 billion acquisition of ProfoundBio last year. The Danish biotech said the asset’s benefit-risk profile no longer justified continuation, leading to the termination of a Phase I/II trial in August.

GEN1107 was designed to target PTK7, a protein broadly expressed in solid tumors. The study enrolled patients with ovarian, endometrial, triple-negative breast, non-small cell lung, gastroesophageal and urothelial cancers. Genmab confirmed that while this program is now halted, it will continue to advance other ProfoundBio-derived assets.

Chief among these is rinatabart sesutecan, a folate receptor alpha-directed ADC currently in Phase II trials for platinum-resistant ovarian and endometrial cancers. The company is also developing GEN1160, which targets CD70, in indications including renal cell carcinoma, nasopharyngeal carcinoma and non-Hodgkin lymphoma. Both remain core parts of Genmab’s pipeline strategy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK